IPH 2101 (NN 1975), developed in collaboration with Novo Nordisk A/S, was administered for the first time in humans

Innate Pharma SA announced today that IPH 2101 (NN 1975), developed by Novo Nordisk A/S in collaboration with Innate Pharma, was administered for the first time in humans.

PR in english 83.41 KB
CP en français 80.53 KB